Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[DNA topoisomerase inhibitor].

T Sugiura1, Y Ariyoshi

  • 1Dept. of Internal Medicine, Aichi Cancer Center, Nagoya, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|November 1, 1992
PubMed
Summary

New chemotherapy drugs CPT-11 and Topotecan inhibit DNA topoisomerase I, showing antitumor activity. Other agents targeting topoisomerase II are in clinical trials, with CPT-11 showing promise for lung cancer patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer.

British journal of cancer·2003
Same author

Progressive development of insulin resistance phenotype in male mice with complete aromatase (CYP19) deficiency.

The Journal of endocrinology·2003
Same author

Post-harvest storage of corn: effect of beginning moisture content on mycoflora and fumonisin contamination.

Food additives and contaminants·2002
Same author

Association between adult-onset Still's disease and interleukin-18 gene polymorphisms.

Genes and immunity·2002
Same author

[Extraction of bisphenol-A from a cardiopulmonary bypass circuit].

Kyobu geka. The Japanese journal of thoracic surgery·2002
Same author

Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance.

Prostaglandins, leukotrienes, and essential fatty acids·2002

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Chemotherapy resistance remains a challenge in cancer treatment.
  • DNA topoisomerases are crucial targets for anticancer drugs.
  • Novel agents targeting topoisomerase I and II are under investigation.

Purpose of the Study:

  • To evaluate the antitumor activity and toxicity of CPT-11 and Topotecan.
  • To assess the efficacy of novel topoisomerase II inhibitors (NC-190, IST-622).
  • To report findings from a Phase II study of CPT-11 in lung cancer patients.

Main Methods:

  • In vitro and in vivo studies of CPT-11 and Topotecan against murine tumors.
  • Clinical trials for NC-190 and IST-622 targeting DNA topoisomerase II.
  • Phase II clinical trial of CPT-11 in patients with advanced non-small cell lung cancer and small cell lung cancer.

Main Results:

  • CPT-11 and Topotecan demonstrated significant antitumor activity with low toxicity in preclinical models.
  • NC-190 and IST-622 target DNA topoisomerase II, with ongoing clinical studies.
  • Phase II study confirmed CPT-11's high activity and acceptable toxicity in advanced lung cancer.

Conclusions:

  • CPT-11 and Topotecan are promising semisynthetic derivatives of CPT with potent antitumor effects.
  • Inhibition of DNA topoisomerase I and II represents a viable strategy for novel cancer therapies.
  • CPT-11 shows significant clinical potential for treating advanced non-small cell and small cell lung cancer.

Related Experiment Videos